tirzepatide and vision Popular weight-loss drugs linked to sudden loss, research suggests vision changes on tirzepatide issues

There is no proven risk of this happening in people

Across all GLP-1 medications, 12-month persistence (still taking the medication at one year) ranges from 38% to 56% depending on the study and population (Wilding et al., Diabetes Obes Metab 2023)

CagriSema is an investigational combination with no approved dose

Phase 2 trials (Jastreboff et al., NEJM, 2023) have shown it to be highly effective for weight reduction in adults with obesity

Topical application is generally considered the lowest risk because very little of the ingredient reaches the bloodstream

Pohl EE, Vazdar M, Kreiter J (2025) Exploring the proton transport mechanism of the mitochondrial ADP/ATP carrier: FA-cycling hypothesis and beyond